Regular article
Bupropion SR and contingency management for adolescent smoking cessation

https://doi.org/10.1016/j.jsat.2010.08.010Get rights and content

Abstract

There is a significant need for evidence-based treatments for adolescent smoking cessation. Prior research, although limited, has suggested potential roles for bupropion sustained-release (SR) and contingency management (CM), but no previous studies have assessed their combined effect. In a double-blind, placebo-controlled design, 134 adolescent smokers were randomized to receive a 6-week course of bupropion SR + CM, bupropion SR + non-CM, placebo + CM, or placebo + non-CM, with final follow-up at 12 weeks. The primary outcome was 7-day cotinine-verified point prevalence abstinence, allowing for a 2-week grace period. Combined bupropion SR + CM treatment yielded significantly superior abstinence rates during active treatment when compared with placebo + non-CM treatment. In addition, combined treatment showed greater efficacy at multiple time points than did either bupropion SR + non-CM or placebo + CM treatment. Combined bupropion SR and CM appears efficacious, at least in the short-term, for adolescent smoking cessation and may be superior to either intervention alone.

Keywords

Bupropion
Contingency management
Nicotine
Smoking
Tobacco
Adolescent
Youth
Treatment

Cited by (0)

Clinical Trials Registry: Combined Pharmaco/Behavior Therapy in Adolescent Smokers; NCT00330187; http://clinicaltrials.gov/ct2/show/study/NCT00330187.

Dr. Gray has received research support from Pfizer, Inc. (medication and placebo supply for research funded by the National Institute on Drug Abuse). Dr. Hartwell has received grant support through Global Research Awards for Nicotine Dependence, an independent competitive grants program supported by Pfizer, Inc. Dr. Hiott is a past speakers' bureau member of Bristol-Myers Squibb and Abbott Labs. Dr. Deas has been an advisory board and speakers' bureau member of Eli Lilly and Company. Dr. Upadhyaya is a past consultant and/or advisory board member of Eli Lilly and Company and Shire Pharmaceuticals. Dr. Upadhyaya is an ex-stockholder of New River Pharmaceutical Company, is a past speakers' bureau member of Shire Pharmaceuticals and Pfizer, Inc., and has received research support from Cephalon, Inc., Eli Lilly and Company, and Pfizer, Inc. Dr. Upadhyaya recently became an employee of, and is a holder of stock in, Eli Lilly and Company. The other investigators deny any potential conflicts of interest.

View Abstract
Copyright © 2011 Elsevier Inc. All rights reserved.